Editas Medicine, Inc. EDIT
Editas Medicine, Inc. (Nasdaq: EDIT) is a cardio-renal-metabolic drug developer. Its lead program, EDIT-401, is in Pre-clinical for Heterozygous familial hypercholesterolemia / elevated LDL-C. Its next catalyst on record is EDIT-401: Editas expects to report initial safety and tolerability data from EDIT-401 Phase 1/2 trial in the first quarter of 2027. (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EDIT-401 — Editas expects to report initial safety and tolerability data from EDIT-401 Phase 1/2 trial in the first quarter of 2027. (Q1 2027). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EDIT-401 | HeFH / hyperlipidemia | gene therapy | Pre-clinical |
Recent results and decisions
- Oct 8, 2026accepted Australian HREC approval and TGA CTN completed for the Phase 1/2 Strive trial of EDIT-401; also submitted in New Zealand.
The trial has received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA)
Filing - Oct 8, 2026started Editas Medicine received approval to initiate Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia in Australia.
The trial has received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia's Therapeutic Goods Administration (TGA) and has also been submitted for review in New Zealand.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.